Bimagrumab Semaglutide Combo V2
TL;DR
The BELIEVE Phase 2 trial (NCT05616013, 507 adults, 72 weeks) found bimagrumab 30 mg/kg IV Q12W + semaglutide 2.4 mg SC weekly achieved −22.1% body weight (−24.2 kg) with −2.9% lean mass and 92% fat loss index. This is the combination’s core value proposition: substantial total weight loss with lean mass preservation, compared to semaglutide alone (−15.7% BW, −7.4% lean mass). Bimagrumab monotherapy achieved 100% fat selectivity but only −10.8% total body weight — insufficient alone. The therapy is investigational only; no regulatory approval exists for the obesity indication; Phase 3 has not been initiated.
Critical framing: The combination loses lean mass (−2.9%). Do not describe it as “muscle building.” Frame it as “lean mass preservation” — specifically, preventing the −7.4% lean loss that semaglutide monotherapy causes. Bimagrumab monotherapy is the only arm with net lean gain (+2.5%), but achieves insufficient total weight loss.
Why it matters for Vitals
Ben is on Retatrutide (GLP-1/GIP/GCGR triple agonist). The lean-mass fraction during GLP-1 therapy is a genuine concern for body recomposition goals:
- The GLP-1 lean mass problem is real and quantified: 25–40% of total weight lost on GLP-1 therapy is lean/fat-free mass (systematic review, PMID 38629387; ACP 2026 presentation, PMID 39481534). This is comparable to bariatric surgery proportions.
- Bimagrumab is the only pharmacological agent in active development with direct lean-gain evidence in humans — but for the combination (not monotherapy), it is a preserver, not a builder.
- DXA monitoring is the gold standard: Consumer BIA scales overestimate fat-free mass by 3–8 kg vs. DXA. Scale weight alone is misleading for body composition tracking on GLP-1 therapy.
- HRV/wearable context: Sustained nocturnal HRV suppression during active weight loss may signal catabolic stress — but on GLP-1 therapy this is confounded by GI side effects, dose titration, and caloric restriction itself. Trends over 2–4 weeks are more reliable than single days.
- Creatinine artifact: Creatinine falls with lean mass loss, potentially masking true kidney function decline. Use cystatin C for renal monitoring during active GLP-1 therapy.
- Coaching flag: Resistance training + protein (1.6–2.2 g/kg/day) remains the only evidence-supported, accessible intervention for GLP-1-induced muscle loss. Bimagrumab is not accessible outside clinical trials.
Key facts
| Claim | Grade | Source |
|---|---|---|
| Combo: −22.1% BW, −2.9% lean mass, 92% FLI at 72 weeks (BELIEVE Phase 2) | Confirmed | PMID 41772149 |
| Bimagrumab monotherapy: 100% FLI but only −10.8% BW at 72 weeks | Confirmed | PMID 41772149 |
| Semaglutide monotherapy: −7.4% lean mass (25–40% lean fraction of total loss) | Confirmed | PMID 41772149 + PMID 38629387 |
| Bimagrumab monotherapy gains lean mass (+2.5% at week 72) | Confirmed | PMID 41772149 |
| Combination is additive, not synergistic — approximately sum of parts | Supported | PMID 41772149 |
| Myostatin inhibitor class: ~95% failure rate in clinical trials | Confirmed | Class history |
| Bimagrumab: muscle spasm rate 41% (monotherapy); transient lipase elevation 10.8% | Confirmed | PMID 41772149, investigator brochure |
| 2 confirmed pancreatitis cases in ~1,038 bimagrumab participants (all indications) | Confirmed | Investigator brochure |
| Bimagrumab + tirzepatide T2D+obesity trial (NCT06901349): terminated Sep 2025 (business, not safety) | Confirmed | ClinicalTrials.gov |
| Bimagrumab + tirzepatide obesity-only trial (NCT06643728): actively recruiting | Confirmed | ClinicalTrials.gov |
| Eli Lilly acquired Versanis Bio (bimagrumab rights): 2023, up to $1.9B | Confirmed | Corporate disclosure |
| Bimagrumab: NOT approved anywhere for obesity/GLP-1 combo | Confirmed | Regulatory status |
| Bimagrumab (Forzinity): FDA-approved Sep 2025 for Barth syndrome only | Confirmed | FDA approval record |
| Bimagrumab SC bioavailability: ~40% (Phase 1, PMID 36527600) | Confirmed | PMID 36527600 |
| No Phase 3 initiated for obesity indication as of Apr 2026 | Confirmed | Development status |
| Bimagrumab cardiac safety (6 months, healthy older adults 70–85): no adverse signal | Supported | PMID 41873146 (JCEM 2026) |
| Bimagrumab in sarcopenic populations: +5.29% thigh muscle volume, but no strength improvement | Confirmed | PMID 39251484 (meta-analysis) |
Mechanism summary
Bimagrumab — ActRII (ACVR2A/ACVR2B) blockade
Bimagrumab is a fully human IgG1 monoclonal antibody targeting activin receptor type IIA and type IIB — the shared signaling receptors for the myostatin/activin/GDF11 axis.
Ligands blocked:
- Myostatin (GDF8)
- GDF11
- Activin A and Activin B
Downstream effects:
-
Relief of proteolysis inhibition — Myostatin/activin signal through ActRII → Smad2/3 phosphorylation → Atrogin-1 (MAFbx) and MuRF1 upregulation → ubiquitin-proteasome proteolysis. Blocking ActRII removes this catabolic brake.
-
Relief of synthesis inhibition — Myostatin/activin also inhibit Akt/mTORC1 signaling. Blocking ActRII relieves this anabolic brake, increasing muscle protein synthesis rate.
-
Net effect: Bimagrumab monotherapy produces net lean gain (+2.5% at 72 weeks). The combination preserves lean mass during GLP-1-driven caloric deficit.
Important caveats:
- Activin B/beige thermogenesis mechanism is preclinical only — not demonstrated in humans. Do not cite as confirmed.
- The combination’s lean preservation is preventive (blocks catabolism from caloric deficit), not additive anabolic (does not produce net new muscle growth on top of GLP-1).
See ActRII Myostatin Pathway for the detailed myostatin/activin signaling mechanism.
Semaglutide — GLP-1 receptor agonism
Semaglutide activates hypothalamic GLP-1R, driving satiety enhancement, caloric deficit, and weight loss. It has no direct effect on skeletal muscle. Lean mass loss during semaglutide therapy is an indirect consequence of caloric restriction, not a direct drug effect.
See GLP-1 GIP Glucagon for the full incretin receptor pharmacology.
Combination rationale
The mechanisms are complementary and non-overlapping:
- Bimagrumab: peripheral (muscle + adipose), anabolic in muscle, lipolytic in fat
- Semaglutide: central (hypothalamus), appetite suppression → caloric deficit
- Combination: combined caloric deficit + muscle preservation
No PK interaction expected (unrelated targets, no CYP450 involvement).
Clinical results
BELIEVE Phase 2 (NCT05616013) — 72-week results
| Arm | Body weight | Lean mass | Fat loss index | VAT |
|---|---|---|---|---|
| Placebo | −3.3% | Not reported | — | — |
| Bimagrumab 10 mg/kg | −6.0% | Not reported | ~90% | — |
| Bimagrumab 30 mg/kg | −10.8% | +2.5% | 100% | −0.4 kg |
| Semaglutide 2.4 mg | −15.7% | −7.4% | 75.6% | −0.4 kg |
| Combo: Bima 30 + Sema 2.4 | −22.1% (−24.2 kg) | −2.9% | 92% | −0.7 kg (p<0.001 vs sema) |
Week 48 primary endpoint (LSM): −17.8 kg combo vs. −14.2 kg semaglutide vs. −9.3 kg bimagrumab vs. −3.3 kg placebo.
Key interpretation:
- The combination’s advantage is total weight loss magnitude + preserved body composition.
- The 92% FLI is not exceptional — bimagrumab alone achieves 100%. The 92% reflects the semaglutide component’s lean mass trade-off.
- Bimagrumab monotherapy: perfect body composition, insufficient total weight loss for obesity treatment.
- Semaglutide monotherapy: substantial weight loss, significant lean mass sacrifice.
- Combination: best of both worlds on paper; practical burden is IV + SC.
T2D + Obesity Phase 2 (NCT03005288, 48 weeks)
75 adults, bimagrumab 10 mg/kg IV Q4W (different dosing):
- Fat mass: −20.5% (−7.5 kg)
- Lean mass: +3.6% (+1.70 kg)
- HbA1c: −0.76 percentage points
- Body weight: −5.8% (−5.2 kg)
Sarcopenic populations meta-analysis (PMID 39251484)
7 RCTs, bimagrumab vs. placebo:
- Thigh muscle volume: MD +5.29% (P<0.001)
- Fat-free mass: MD +1.90 kg (P<0.001)
- Fat mass: MD −4.55 kg (P<0.001)
- Muscle strength: no significant improvement
- Physical performance: no significant improvement
⚠️ Critical functional disconnect warning: Pharmacological lean mass gain does not automatically translate to strength, mobility, or functional improvement. The BELIEVE trial did not measure strength or functional endpoints. The sIBM/sarcopenia dataset is the only long-term human bimagrumab dataset with functional measures — and it shows a clear disconnect between muscle volume and function. Do not use DXA lean mass as a proxy for functional capacity on bimagrumab.
Safety
Adverse event rates
| Adverse event | Bimagrumab mono | Semaglutide mono | Combination |
|---|---|---|---|
| Muscle spasms | 41% | Not prominent | Most common bimagrumab AE |
| Diarrhea | 41% | ~30% | Consistent |
| Nausea | 11% | ~30% | Consistent |
| Lipase elevation (transient) | 10.8% | — | Monitor |
| Acne | Yes | — | Reported |
| LDL increase (transient) | Yes | — | Less in statin users |
Serious adverse events
- 9 serious events in 6 patients across Phase 2 T2D trial
- 2 confirmed acute pancreatitis cases in ~1,038 bimagrumab participants across all indications (investigator brochure). Semaglutide carries its own pancreatitis risk. Combination pancreatitis risk is unquantified and potentially compounding.
- Discontinuation due to AEs: bimagrumab 30 mg/kg mono 21.4%; combo high dose 12.5%.
Cardiac safety
- 6 months bimagrumab in healthy older adults (70–85 years): no effect on cardiac structure or function by echocardiography and cardiac MRI (PMID 41873146, JCEM 2026).
- ActRIIB is expressed on cardiac muscle — long-term cardiac safety in patients with pre-existing cardiac disease remains unstudied.
- No MACE data for the combination.
What is unknown
- Long-term (>72 week) combination safety
- Chronic bone mineral density during ActRII blockade
- Cancer risk with long-term activin pathway blockade (GDF11/activin in tumor biology)
- Pancreatitis risk in the combination specifically
- Safety in pregnancy
Regulatory and development status
| Item | Status |
|---|---|
| Bimagrumab approved (any indication) | No — investigational only |
| Bimagrumab (Forzinity) — Barth syndrome | FDA-approved September 2025 |
| Bimagrumab — obesity/GLP-1 combo | NOT approved — investigational only |
| Semaglutide 2.4 mg (Wegovy) | Approved (FDA 2021) |
| Development path | Novartis → Roche → Versanis Bio → Eli Lilly ($1.9B, 2023) |
| BELIEVE Phase 2 (NCT05616013) | Completed Mar 2026; Nature Medicine published |
| NCT06901349 (bima + tirzepatide, T2D+obesity) | Terminated Sep 2025 — strategic business reasons |
| NCT06643728 (bima ± tirzepatide, obesity only) | Actively recruiting — Eli Lilly sponsor |
| NCT05933499 (MGH, tirzepatide + bima) | Actively enrolling — investigator-initiated |
| Phase 3 | Not initiated |
⚠️ The NCT06901349 termination is a commercial signal, not a safety or efficacy failure. Lilly terminated the T2D+obesity arm for “strategic business reasons.” This does not mean bimagrumab is unsafe or ineffective — but it signals commercial uncertainty. Phase 3 has not been announced. Estimated timeline to potential approval: 3–6+ years minimum, assuming Phase 3 starts promptly.
Comparative effectiveness
⚠️ All comparisons are indirect (cross-trial). Different populations, baselines, durations, and designs. Cannot be used for clinical superiority claims.
| Agent / Regimen | Approx. weight loss | Lean mass effect | Route | Phase |
|---|---|---|---|---|
| Bimagrumab 30 + Semaglutide 2.4 | −22.1% (~−24 kg) | Preserved (−2.9%) | IV Q12W + SC weekly | Phase 2 |
| Semaglutide 2.4 mg (STEP-1) | ~15.3 kg (~14.9%) | ~25–35% as lean | SC weekly | Approved |
| Tirzepatide 15 mg (SURMOUNT-1) | ~20–22 kg (~20–22%) | Estimated ~25–35% as lean | SC weekly | Approved |
| Retatrutide (Phase 2) | ~24–26 kg (~24%) | Estimated ~25–35% as lean | SC weekly | Phase 3 |
| Bimagrumab 30 mg/kg alone | −10.8% | Gains (+2.5%) | IV Q12W | Phase 2 |
| Bariatric surgery | 25–35% at 1–2 yr | Variable | Surgical | Established |
The combo’s value proposition is specifically lean mass preservation, not raw weight loss superiority. Indirect data suggest tirzepatide and retatrutide monotherapy may achieve comparable or greater total weight loss without IV burden. No head-to-head data exist.
Vitals relevance
Body composition monitoring
| Timepoint | Method | What to track |
|---|---|---|
| Baseline (week 0) | DXA (gold standard) | Lean mass, fat mass, VAT, appendicular lean |
| Week 12 | BIA (consumer scale) | Directional lean/fat trend |
| Week 24 | DXA | Confirm lean preservation; compare to BELIEVE reference |
| Week 36 | BIA | Directional trend |
| Week 48 | DXA | Primary endpoint comparison; full body composition |
| Ongoing (quarterly) | BIA | Trend monitoring between DXA visits |
- DXA: Gold standard for body composition; used in BELIEVE. Cost ~USD 100–300/scan; limited access. Recommend baseline + every 24 weeks minimum.
- BIA: Consumer scales (Withings, InBody, Tanita). Accuracy ±2–4% for muscle mass; influenced by hydration, food intake. Suitable for trend monitoring, not diagnostic accuracy.
- VAT: Consumer wearables cannot measure VAT. CT or MRI required.
Wearable algorithm hooks
| Signal | Expected direction | Confidence | Coaching action |
|---|---|---|---|
| DXA lean mass | Declining during GLP-1 therapy without intervention | High | Review protein intake, training load |
| BIA lean mass trend | Declining — misleading without DXA context | Moderate | Use for trend, not absolute values |
| Grip strength | May improve despite lean mass loss (functional adaptation) | Moderate | Better proxy than scale weight |
| Nocturnal HRV | Weight loss generally improves HRV; sustained suppression may signal catabolic overreaching | Low-moderate | Needs trend not single day; confounded by GI, alcohol, illness |
| Resting HR | GLP-1 agents can raise RHR +5–10 bpm (Retatrutide dysesthesia signal) | Moderate | Separate from weight-loss HR reduction |
| Creatinine | Falsely declining with muscle mass loss | Confound | Use cystatin C for kidney function monitoring |
Coaching flags
- IV burden: Bimagrumab requires IV infusion every 12 weeks. Not a simple injectable add-on.
- Cost: Estimated 1,000/month. Total: $11,000+/month.
- Accessibility: Not approved; not accessible outside clinical trials.
- Muscle spasm rate (41%): Most notable bimagrumab-specific adverse event. Magnesium supplementation, hydration, stretching may help.
- Lipase monitoring: Transient elevation 10.8%. Combination pancreatitis risk is unquantified.
- Resistance training: Bimagrumab potentiates but does not replace the muscle anabolic response to mechanical load. Continue training.
- No functional guarantee: Lean mass gain ≠ strength gain. Do not use DXA as sole outcome.
Risks and uncertainty
- Phase 3 not initiated: Regulatory approval is 3–6+ years away minimum.
- Commercial uncertainty: One combination trial already terminated for business reasons.
- Myostatin inhibitor class failure rate: ~95% failure rate in clinical trials. Bimagrumab is the exception, not the rule.
- Functional disconnect: Pharmacological lean gain does not equal functional improvement.
- No MACE data: Long-term cardiac outcomes unknown.
- Bone safety gap: Chronic ActRII blockade effect on bone mineral density uncharacterized.
- T2D population: BELIEVE excluded diabetics; ~37% of US adults with obesity have T2D.
- Diversity gap: 75% White, 3% Black, 3% Asian in BELIEVE. Results may not generalize.
Best stack context
For GLP-1 users concerned about muscle loss (accessible now):
| Tier | Intervention | Evidence Grade |
|---|---|---|
| 1 | Protein 1.6–2.2 g/kg/day + resistance training 2–3×/week | Confirmed — only interventions with robust functional outcome data |
| 2 | Creatine monohydrate 5 g/day | Supported — good evidence for LBM preservation during caloric restriction |
| 3 | Consider tirzepatide over semaglutide if body composition is a priority | Supported — numerically better relative LBM preservation in cross-trial comparison |
Bimagrumab combination (when/if approved and accessible):
- Continue resistance training — bimagrumab potentiates, not replaces, mechanical loading
- Muscle spasm management: magnesium, hydration, stretching
- DXA at baseline, 24 weeks, 48 weeks
- Lipid panel monitoring (transient LDL elevation)
- Pancreatic enzyme monitoring
Related notes
Mechanisms
- ActRII Myostatin Pathway — myostatin/activin signaling; bimagrumab mechanism
- GLP-1 GIP Glucagon — GLP-1/GIP/GCGR receptor pharmacology
- mTOR AMPK Muscle Catabolism — signaling pathway governing muscle protein synthesis vs. breakdown during caloric deficit
Clinical Context
- GLP-1 Muscle Preservation — the parent hub for lean mass issues during GLP-1 therapy
- Retatrutide — Ben’s primary GLP-1 agent; lean mass impact expected
- Bimagrumab Semaglutide Combo Obesity — superseded by this V2 note (Batch 43/49 origin)
Biometrics / Protocols
- HRV — wearable recovery signal; catabolic stress detection
- HRV Guided Training — HRV-based training decisions
- Resistance Training for Longevity — the evidence-backed anchor for muscle preservation
Evidence summary
| Claim | Grade | Verdict |
|---|---|---|
| Combo achieves −22.1% BW at 72 weeks (BELIEVE) | Confirmed | High confidence |
| Combo lean mass change −2.9% (vs. −7.4% semaglutide alone) | Confirmed | High confidence |
| Bimagrumab monotherapy gains lean mass (+2.5% at 72 weeks) | Confirmed | High confidence |
| Bimagrumab monotherapy: 100% FLI | Confirmed | High confidence |
| 92% FLI for combo is not exceptional (bimagrumab alone is 100%) | Confirmed | Empirically true |
| Combination is additive, not synergistic | Supported | Mechanistic inference |
| Bimagrumab + tirzepatide T2D+obesity trial terminated (business reasons) | Confirmed | Regulatory status |
| Bimagrumab + tirzepatide obesity-only trial actively recruiting | Confirmed | ClinicalTrials.gov |
| Bimagrumab: investigational only; not approved for obesity | Confirmed | Regulatory status |
| Bimagrumab (Forzinity) approved for Barth syndrome Sep 2025 | Confirmed | FDA approval |
| Muscle spasm rate 41% (bimagrumab monotherapy) | Confirmed | Clinical data |
| 2 pancreatitis cases in ~1,038 bimagrumab participants | Confirmed | Investigator brochure |
| Myostatin inhibitor class: ~95% clinical failure rate | Confirmed | Class history |
| Bimagrumab improves strength/mobility in sarcopenic populations | Refuted | PMID 39251484 |
| GLP-1 lean mass loss: 25–40% of total weight lost | Confirmed | PMID 38629387 |
| Bimagrumab cardiac safety (6 months, healthy older adults): no adverse signal | Supported | PMID 41873146 |
| Phase 3 required before obesity approval | Confirmed | Regulatory status |
| ~3–6 years to potential regulatory approval | Estimated | Development timeline |
Status: Investigational — NOT approved for obesity/GLP-1 combo. Bimagrumab (Forzinity) approved for Barth syndrome only (Sep 2025). Phase 3 not initiated. One combination trial terminated. This note is not clinical guidance. Vitals Monograph — Batch 134 — Bimagrumab + Semaglutide Combination V2 Sources: PMID 41772149 (BELIEVE, Nat Med, Mar 2026); PMID 33439265 (T2D+obesity Phase 2); PMID 38629387 (GLP-1 lean mass systematic review); PMID 39251484 (sarcopenia meta-analysis); PMID 41873146 (cardiac safety); PMID 36527600 (SC bioavailability)